<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02211261</url>
  </required_header>
  <id_info>
    <org_study_id>B3501001</org_study_id>
    <nct_id>NCT02211261</nct_id>
  </id_info>
  <brief_title>A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 1 Double-blind, Placebo-controlled, Randomized, Single- And Multiple-ascending Dose Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Pf-06293620 In Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A first in human study to determine the safety, tolerability and pharmacokinetics of single
      and multiple ascending doses of PF-06293620 in subjects with Type 2 Diabetes Mellitus
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) - Single Ascending Dose Cohorts (SAD)</measure>
    <time_frame>Between days -1 to 85</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 85 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) related to drug treatment- Single Ascending Dose Cohorts (SAD)</measure>
    <time_frame>Between days -1 and 85</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug with the possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment related AEs are events between first dose of study drug and up to 85 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose limiting or intolerable adverse events - SAD Cohorts</measure>
    <time_frame>Between days -1 and 85</time_frame>
    <description>Dose-limiting or intolerable toxicities defined by common terminology criteria for adverse events (CTCAE) in 2 or more subjects per treatment arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of immunogenicity - SAD Cohorts</measure>
    <time_frame>Day -1, 15, 29, 57 and 85</time_frame>
    <description>presence of anti-drug antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) - Multiple Ascending Dose Cohorts (MAD)</measure>
    <time_frame>Between days -1 to 169</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 85 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) related to drug treatment- Multiple Ascending Dose Cohorts (MAD)</measure>
    <time_frame>Between days -1 and 169</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug with the possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment related AEs are events between first dose of study drug and up to 85 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose limiting or intolerable adverse events - MAD Cohorts</measure>
    <time_frame>Between days -1 and 169</time_frame>
    <description>Dose-limiting or intolerable toxicities defined by common terminology criteria for adverse events (CTCAE) in 2 or more subjects per treatment arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of immunogenicity - MAD Cohorts</measure>
    <time_frame>Day -1, 15, 29, 57, 85, 113, 141 and 169</time_frame>
    <description>presence of anti-drug antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) - SAD Cohorts</measure>
    <time_frame>Days 1-15,22,29,43,57 and 85</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 85)] - SAD Cohorts</measure>
    <time_frame>Days 1-15,22,29,43,57 and 85</time_frame>
    <description>AUC (0 - 85)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 85). It is obtained from AUC (0 - t) plus AUC (t - 8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) - SAD Cohorts</measure>
    <time_frame>Days 1-15,22,29,43,57, and 8</time_frame>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) - SAD Cohorts</measure>
    <time_frame>Days 1-15,22,29,43,57 and 85</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)-SAD Cohorts</measure>
    <time_frame>Days 1-15,22,29,43,57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)- SAD Cohorts</measure>
    <time_frame>Days 1-15,22,29,43,57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)- SAD Cohorts</measure>
    <time_frame>Days 1-15,22,29,43,57 and 85</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)- SAD Cohorts</measure>
    <time_frame>Days 1-15,22,29,43,57 and 85</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) - MAD Cohorts</measure>
    <time_frame>Days 1-15,22,27, 28,29,43,57,58, 59, 63, 64, 71, 78, 84, 85, 99, 113, 141 and 169</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 85)] - MAD Cohorts</measure>
    <time_frame>Days 1-15,22,27, 28,29,43,57,58, 59, 63, 64, 71, 78, 84 and 85</time_frame>
    <description>AUC (0 - 85)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 85). It is obtained from AUC (0 - t) plus AUC (t - 8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) - MAD Cohorts</measure>
    <time_frame>Days 1-15,22,27,28,29,43,57,58, 59, 63, 64, 71, 78, 84, 85, 99, 113, 141 and 169</time_frame>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) - MAD Cohorts</measure>
    <time_frame>Days 1-15,22,27, 28,29,43,57,58, 59, 63, 64, 71, 78, 84, 85, 99, 113, 141 and 169</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)-MAD Cohorts</measure>
    <time_frame>Days 1-15,22,27, 28,29,43,57,58, 59, 63, 64, 71, 78, 84, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)- MAD Cohorts</measure>
    <time_frame>Days 1-15,22,27, 28,29,43,57,58, 59, 63, 64, 71, 78, 84 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)- MAD Cohorts</measure>
    <time_frame>Days 1-15,22,27, 28,29,43,57,58, 59, 63, 64, 71, 78, 84, 85, 99, 113, 141 and 169</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)- MAD Cohorts</measure>
    <time_frame>Days 1-15,22,27, 28,29,43,57,58, 59, 63, 64, 71, 78, 84, 85</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cohort 1-PF-06293620 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose PF-06293620 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2-PF-06293620 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose PF-06293620 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3-PF-06293620 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose PF-06293620 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4-PF-06293620 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose PF-06293620 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5-PF-06293620 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose PF-06293620 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6-PF-06293620 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Ascending Dose PF-06293620 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 PF-06293620 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Ascending Dose PF-06293620 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8-PF-06293620 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Ascending Dose PF-06293620 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9-PF-06293620 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Ascending Dose PF-06293620 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06293620</intervention_name>
    <description>subcutaneous, single dose 0.3 mg/kg</description>
    <arm_group_label>Cohort 1-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous normal saline single dose</description>
    <arm_group_label>Cohort 1-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06293620</intervention_name>
    <description>Subcutaneous, single dose 1.0 mg/kg</description>
    <arm_group_label>Cohort 2-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous normal saline single dose</description>
    <arm_group_label>Cohort 2-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06293620</intervention_name>
    <description>Subcutaneous single dose 3 mg/kg</description>
    <arm_group_label>Cohort 3-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous normal saline single dose</description>
    <arm_group_label>Cohort 3-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06293620</intervention_name>
    <description>Subcutaneous single dose 6 mg/kg</description>
    <arm_group_label>Cohort 4-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous normal saline single dose</description>
    <arm_group_label>Cohort 4-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06293620</intervention_name>
    <description>Intravenous infusion single dose 1 mg/kg</description>
    <arm_group_label>Cohort 5-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion normal saline single dose</description>
    <arm_group_label>Cohort 5-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06293620</intervention_name>
    <description>Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)</description>
    <arm_group_label>Cohort 6-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)</description>
    <arm_group_label>Cohort 6-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06293620</intervention_name>
    <description>Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)</description>
    <arm_group_label>Cohort 7 PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)</description>
    <arm_group_label>Cohort 7 PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06293620</intervention_name>
    <description>Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)</description>
    <arm_group_label>Cohort 8-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)</description>
    <arm_group_label>Cohort 8-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06293620</intervention_name>
    <description>Subcutaneous injection multiple dose TBD mg (Days TBD)</description>
    <arm_group_label>Cohort 9-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection normal saline multiple dose (Days TBD)</description>
    <arm_group_label>Cohort 9-PF-06293620 or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women of non-childbearing potential with Type 2 Diabetes Mellitus

          -  Subjects on stable doses of metformin &gt;/= 1500 mg daily (SAD cohorts) or &gt;/= 1000 mg
             daily (MAD cohorts) x 30 days prior to screening

          -  HbA1c 7-10% (SAD Cohorts) or 6.5-10% (MAD cohorts) inclusive at screening

          -  Fasting C-peptide &gt;1.12 ng/mL (SAD cohorts) or &gt;/= 0.8 mg/mL (MAD cohorts) at
             screening

        Exclusion Criteria:

          -  History of Type 1 diabetes mellitus

          -  Evidence of diabetic complications with significant end-organ damage

          -  History of chronic pancreatitis or at high risk for pancreatitis

          -  Poorly controlled hypertension

          -  History of cardiovascular or cerebrovascular event or procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research, Incorporated</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qps Mra, Llc</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qps-Mra Llc</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Point Clinical Trials Center, LLC</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3501001&amp;StudyName=A%20Phase%201%20Single%20Dose%20Study%20Of%20PF-06293620%20To%20Assess%20Safety%2C%20Tolerability%20And%20Pharmacokinetics%20In%20Subjects%20With%20Type%202%20Diabetes%20Mell</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2014</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>first in human</keyword>
  <keyword>single dose</keyword>
  <keyword>multiple dose</keyword>
  <keyword>escalation</keyword>
  <keyword>safety study</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 22, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

